Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 6, 1997, Pages 468-472

  Kakumu, Shinichi ^a   Aiyama, Toshiyuki ^b   Okumura, Akihiko ^a   Iwata, Kazuo ^b   Ishikawa, Tetsuya ^a   Yoshioka, Kentaro ^b  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

hepatitis C; hepatitis C virus; interferon therapy; long term response; predictive factors; reverse transcription polymerase chain reaction

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIREMIA;

EID: 0030985850     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00468.x     Document Type: Article

References (21)

1. Yoshioka K, Kakumu S, Wakita T et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
2. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
3. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-83.
4. Kobayashi Y, Watanabe S, Konishi M et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-β. Hepatology 1993; 18: 1319-25.
5. Lau JYN, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
6. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J. Hepatol. 1994; 21: 1-3.
7. Marcellin P, Pouteau M, Martinot-Peignoux M et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156-65.
8. Booth JCL, Foster GR, Kumar U et al. Chronic hepatitis C virus infections: Predictive value of genotype and level of viraemia on disease progression and response to interferon a. Gut 1995; 36: 427-32.
9. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-α therapy. Ann. Intern. Med. 1995; 122: 586-91.
10. Hino K, Okuda M, Konishi T, Ishiko H, Okita K. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-α therapy. Dig. Dis. Sci. 1995; 40: 14-20.
11. Onto E, Mizokami M, Suzuki K et al. Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J. Med. Virol. 1995; 46: 109-15.
12. Young KY, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J. Clin. Microbiol. 1993; 31: 882-6.
13. Aiyama T, Yoshioka K, Hirofuji H et al. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C. Dig. Dis. Sci. 1994; 39: 2244-9.
14. Zeuzem S, Ruster B, Roth WK. Clinical evaluation of a new polymerase chain reaction assay (Amplicor™ HCV) for detection of hepatitis C virus. Z. Gastroenterol. 1994; 32: 342-7.
15. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J. Gen. Virol. 1992; 73: 673-9.
16. Simmonds P, McOmish F, Yap PL et al. Sequence variability in the 5′ non-coding region of hepatitis C virus: Identification of a new virus type and restrictions on sequence diversity. J. Gen. Virol. 1993; 74: 661-8.
17. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N. Engl. J. Med. 1995; 332: 1457-62.
18. Oshita M, Hayashi N, Kasahara A et al. Sixteen-week treatment exhibits a similar efficacy of interferon therapy to 24-week treatment in chronic hepatitis C patients with genotype 2a and 2b. Hepatology 1994; 20: 155A (Abstract).
19. Marcellin P, Castelnau C, Milotova V et al. Influence of the dose and of the duration of interferon treatment on the response to therapy according to HCV genotype in chronic hepatitis C. Hepatology 1994; 20: 155A (Abstract).
20. Balart LA, Perrillo R, Roddenberry J et al. Hepatitis C virus RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. Gastroenterology 1993; 104: 1472-7.
21. Saleh MG, Tibbs CJ, Koskinas J et al. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 1994; 20: 1399-404.